Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artículo Open Access |
| Publié: |
Wiley
2025
|
| Sujets: | |
| Accès en ligne: | https://onlinelibrary.wiley.com/doi/10.1002/jca.70087 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Table des matières:
- Twenty‐Four Cases of Severe ANCA ‐Associated Vasculitis Treated With Plasma Exchange: A Clinical Analysis and Long‐Term Follow‐Up Zhou Chen Wenhao Li Zhiyong Guo Chao Zhu Journal of Clinical Apheresis ABSTRACT Advances in the understanding of anti‐neutrophil cytoplasmic antibodies (ANCA)‐associated vasculitis (AAV) pathophysiology have expanded the application of plasma exchange (PE) in severe cases; however, robust evidence on its efficacy, safety, and long‐term outcomes remains scarce. This retrospective study evaluated the short‐term efficacy, safety, and long‐term prognosis of PE in patients with severe AAV. A total of 24 patients receiving PE alongside standard induction therapy (glucocorticoids plus cyclophosphamide or rituximab) were analyzed. Clinical and laboratory parameters—including ANCA titers, Birmingham Vasculitis Activity Score (BVAS), C‐reactive protein (CRP), and hemoglobin (Hb)—were assessed before and after treatment, together with adverse events and survival. The cohort comprised 10 males and 14 females, mean age 62.5 ± 16.1 years (range 29–84). PE was associated with significant reductions in ANCA levels, BVAS, and CRP, alongside increased Hb. Over long‐term follow‐up, mortality rose progressively, mainly attributable to severe infections, respiratory failure, and heart failure. In conclusion, PE exhibits short‐term effectiveness and a tolerable safety profile in severe AAV, yet long‐term survival outcomes warrant further attention. 10.1002/jca.70087 http://onlinelibrary.wiley.com/termsAndConditions#vor